Literature DB >> 27504069

Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

Chris Fellner.   

Abstract

Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.

Entities:  

Year:  2016        PMID： 27504069      PMCID： PMC4959621     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].

Authors:  H Rexer
Journal:  Urologe A       Date:  2015-10       Impact factor: 0.639

2.  Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Authors:  Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

3.  [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].

Authors:  H Rexer; C Doehn
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

Review 4.  The epidemiology of renal cell carcinoma.

Authors:  Börje Ljungberg; Steven C Campbell; Han Yong Choi; Han Yong Cho; Didier Jacqmin; Jung Eun Lee; Steffen Weikert; Lambertus A Kiemeney
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

5.  Body mass index, physical activity, and risk of renal cell carcinoma.

Authors:  B C-H Chiu; S M Gapstur; W-H Chow; K A Kirby; C F Lynch; K P Cantor
Journal:  Int J Obes (Lond)       Date:  2006-06       Impact factor: 5.095

6.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

7.  Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Authors:  Asim Amin; Arkadiusz Z Dudek; Theodore F Logan; Raymond S Lance; Jeffrey M Holzbeierlein; Jennifer J Knox; Viraj A Master; Sumanta K Pal; Wilson H Miller; Lawrence I Karsh; Irina Y Tcherepanova; Mark A DeBenedette; W Lee Williams; Douglas C Plessinger; Charles A Nicolette; Robert A Figlin
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751

Review 8.  PD-1 as a potential target in cancer therapy.

Authors:  David F McDermott; Michael B Atkins
Journal:  Cancer Med       Date:  2013-07-21       Impact factor: 4.452
  8 in total
  1 in total

Review 1.  The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.

Authors:  Pedro C Barata; Moshe C Ornstein; Jorge A Garcia
Journal:  J Kidney Cancer VHL       Date:  2017-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.